Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $45.1 million.

  • Voyager Therapeutics' Cash & Equivalents fell 59.90% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year decrease of 59.90%. This contributed to the annual value of $71.4 million for FY2024, which is 3.73% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Cash & Equivalents is $45.1 million, which was up 2.70% from $43.9 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Cash & Equivalents peaked at $268.3 million during Q1 2023, and registered a low of $43.9 million during Q2 2025.
  • Over the past 3 years, Voyager Therapeutics' median Cash & Equivalents value was $74.8 million (recorded in 2025), while the average stood at $110.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 211.88% in 2023, then slumped by 68.84% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Cash & Equivalents (Quarterly) stood at $117.4 million in 2021, then dropped by 15.73% to $99.0 million in 2022, then plummeted by 30.47% to $68.8 million in 2023, then increased by 3.73% to $71.4 million in 2024, then tumbled by 59.90% to $45.1 million in 2025.
  • Its last three reported values are $45.1 million in Q3 2025, $43.9 million for Q2 2025, and $74.8 million during Q1 2025.